Search Within
Document Type
117-92-0
Applied Filters:
Keyword:'117-92-0'
Showing 1-30 of 207 results for "117-92-0" within Technical Documents
The Effective Use of Protein Kinase Inhibitors
34 37 57 87 81 26 104 70 64 75 61 92 102 55 106 53 85 101
95 100 95 103 88 82 81 98
91 84 21 128 89 98 98 99 103 38 99 76
The Effective Use of Protein Kinase Inhibitors
34 37 57 87 81 26 104 70 64 75 61 92 102 55 106 53 85 101
95 100 95 103 88 82 81 98
91 84 21 128 89 98 98 99 103 38 99 76
MILLIPLEX®MAP Human Myokine Panel is an optimized quantitative immunoassay that simultaneously measures 15 novel muscle-secreted factors
136 28
std
7
21 12 43 8686 117 43 27 97 15 44 26 33 29 127 27
19 12 37 8809 118 44 29 92 15 46 25 33 29 130 27
SPARC std
Product Information Sheet - A2181
respectively).9
REFERENCES:
1. R.M.C. Dawson, et. al., Data for Biochemical Research, 3rd ed., 116-117 (1993).
2. Sigma data.
3. E.J. Simon and D. Shemin, J. Am. Chem. Soc., 75, 2520, (1953).
4. E.R.
Product Information Sheet - BSTXIRO
Restriction Endonuclease Bst XI
From Bacillus stearothermophilus XI
Cat. No. 11 117 777 001 250 units (10 U/�l)
Cat. No. 11 117 785 001 1250 units (10 U/�l)
y Version 18
Content version: May 2011
Store
Spare parts for Mobius® FlexReady Solution with Smart Flexware® Assemblies For Chromatography and TFF
(pH/UV/Conductivity)
LOCALE SECTION
D-D
117
119
120
121
123 118
Includes TC gasket
and set of o-rings
for instrumentation
119
117
121
120
123 118
38
7.
LABORATORY NOTEBOOK ISSUANCE PAGE
38
88
.9
06
91
.2
24
92
.9
06
95
.9
6
(9
8)
10
1.
07
10
2.
91
13
8.
91
17
8.
49
18
0.
95
18
3.
84
18
6.
21
19
0.
23
LABORATORY NOTEBOOK ISSUANCE PAGE
38
88
.9
06
91
.2
24
92
.9
06
95
.9
6
(9
8)
10
1.
07
10
2.
91
13
8.
91
17
8.
49
18
0.
95
18
3.
84
18
6.
21
19
0.
23
LABORATORY NOTEBOOK ISSUANCE PAGE
38
88
.9
06
91
.2
24
92
.9
06
95
.9
6
(9
8)
10
1.
07
10
2.
91
13
8.
91
17
8.
49
18
0.
95
18
3.
84
18
6.
21
19
0.
23
Human Neuropeptide S (NPS) ELISA
mL
% of
Recovery
0 92 92
313 405 407 100
625 717 814 114
1
1250 1342 1658 124
0 0 0
313 313 361
Free Fraction Analysis for Therapeutic Drug Monitoring of Antiepileptic Drugs
transitions (Table 1)
injection: 1 µL
gradient: hold 0%B for 1 min, 0% to 80%B in 2 min, hold 80%B for 1
min, to 0%B in 0.1 min and hold at 0%B for 1.9 min
User Guide-RAB0609
105 86-117
Linearity
Sample Type Serum Plasma Cell Culture Supernatants
1:2
Average % of Expected 87 96 98
Range (%) 82-92 84-109 95-101
1:4
Average % of Expected Range 95 102 117
Range
User Guide-RAB0522
Cell Culture Supernatants 109 92-131
Linearity
Sample Type Serum Plasma Cell Culture Supernatants
1:2
Average % of Expected 87 117 107
Range (%) 79-96 70-130 98-117
1:4
Average % of Expected
User Guide-RAB1464
as follows:
Sample Type Average % Recovery Range (%)
Serum 78 68-92
Plasma 74 67-90
Cell Culture Supernatants 107 97-117
Linearity
Sample Type Serum Plasma Cell Culture Supernatants
S.D.S. and Accessories
Reservoir inlet
Purified air enters the reservoir
10
1 32 54 76 98 1110 1312 14 15
20 30 40 50
117 V
230 V
1
2
3
4
10
User Guide-RAB0193
Average % of Expected 104 110 113
Range (%) 94-111 102-117 104-122
1:4
Average % of Expected Range 82 111 124
Range (%) 70-90 103-117 114-133
4
RAB0193pis Rev 08/24
Product Information Sheet - 11117807001
slow cleavage sites on adenovirus DNA.
� Ad2 SV40 � X174 M13mp7 pBR322 pBR328 pUC18
4 33 0 1 0 0 0 0
0717.111215610019
Ligation and
recutting assay
Ksp I fragments obtained by complete
Validation and Qualification for Durapore® Sterilizing-Grade (0.22 µm) Membrane VMF4
Table 1.
47 10.1 3.72 115 55 13.6 7.45 108
46 10.3 3.77 116 43 13.6 7.55 104
38 9.7 3.85 117 8 13.4 7.60 105
37 10.0 3.94 116 45 13.4 7.64 101
39
User Guide-RAB0381
Plasma 79 65-92
Cell Culture Supernatants 108 94-117
Linearity
Sample Type Serum Plasma Cell Culture Supernatants
1:2
Average % of Expected 107 103 103
Range (%) 95-114 91-113 92-112
1:4
User Guide-RAB0426
Average % of Expected 102 108 104
Range (%) 91-113 94-115 92-116
1:4
Average % of Expected Range 105 110 106
Range (%) 94-110 95-119 92-117
4
RAB0426pis Rev 08/24
Protocol: Mouse Lipocalin-2/NGAL
125 125.0 106.96 86%
8 31.25 46.1 42.38 92%
62.5 77.3 71.37 92%
125 139.8 124.39 89%
9 31.25 31.3 29.21 93%
62.5 62.5 57.3 92%
Neutralizing Efficiency of Lecithin and Polysorbate 80 in ICR Contact Plates and Swabs for Surface Monitoring
89
104
111
85
97
80
109
99
84
91
117
101
108
99
109
99
128
87
108
83
92 95 93
159
126 125
0
20
Influence of Environmental Sample Pre-Storage on Counting Results
striatum
K. rhizophila
P. commune
E. coli
96
106
121
119
86
86 88 91 101
112 94 95 117
118 120 111 122
99 105 86 116
92 78 93 100
R
ec
ov
er
y
R
at
e
(%
)
Figure 1: Recovery Rates
Product Information Sheet - CS0002
per
well (nmol)*
0 µL (Standard
Blank)
100 µL 0
1 µL 99 µL 0.1
2 µL 98 µL 0.2
3 µL 97 µL 0.3
4 µL 96
Corticotropin-Releasing Factor Receptor Antagonists- Potential Novel Therapies for Human Disease
Proc. Natl. Acad. Sci. USA, 92, 836-840 (1995).
14. Kishimoto, T. et al., Proc. Natl. Acad. Sci. USA, 92, 1108-1112 (1995).
15. Perrin, M., et al., Proc. Natl. Acad. Sci. USA, 92, 2969-2973 (1995).
16. Hauger
Product Information Sheet - 10775207001
Inactivation The enzyme can be heat-inactivated by heating to
65°C for 15 min.
A B L M H
100% 0-10% 0–10% 10–25% 0–10%
Component Final concentration
DNA 1 �g
10 × SuRE/Cut Buffer A 2.5 �l
Sterile redist
User Guide-MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel B Magnetic Bead Panel
MCP-4 92% 90%
MIP-1δ 95% 92%
MIP-3α 92% 91%
I-TAC 89% 88%
MIP-3β 99% 92%
MPIF-1 91% 90%
SCF 88% 85%
SDF-1 98% 94%
User Guide-HCYTB60K
MCP-4 92% 90%
MIP-1δ 95% 92%
MIP-3α 92% 91%
I-TAC 89% 88%
MIP-3β 99% 92%
MPIF-1 91% 90%
SCF 88% 85%
SDF-1 98% 94%
User Guide
MCP-4 92% 90%
MIP-1δ 95% 92%
MIP-3α 92% 91%
I-TAC 89% 88%
MIP-3β 99% 92%
MPIF-1 91% 90%
SCF 88% 85%
SDF-1 98% 94%
Protocol- HCYTB-60K|HCYTB-60K-PX38|HCYTB-60K-PXBK38|HCYTB-60K-PX48|HCYTB-60K-PXBK48|HCYTPB-76K|HCYTPAB-76SK|HCYTPB-96K|HCYTPAB-96SK
MCP-4 92% 90%
MIP-1δ 95% 92%
MIP-3α 92% 91%
I-TAC 89% 88%
MIP-3β 99% 92%
MPIF-1 91% 90%
SCF 88% 85%
SDF-1 98% 94%
Page 1 of 7